Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease.
Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Kubota K, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Sekiguchi H, Schleinitz N, Stone JR, Takahashi N, Umehara H, Webster G, Zen Y, Stone JH; American College of Rheumatology/European League Against Rheumatism IgG4-Related Disease Classification Criteria Working Group. Wallace ZS, et al. Among authors: umehara h. Arthritis Rheumatol. 2020 Jan;72(1):7-19. doi: 10.1002/art.41120. Epub 2019 Dec 2. Arthritis Rheumatol. 2020. PMID: 31793250
[Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Research Program of Intractable Disease provided by the Ministry of Health, Labor, and Welfare of Japan].
Research Committee to establish diagnostic criteria and development of treatment for systemic IgG4-related sclerosing disease; Research Committee to establish a new clinical entity, IgG4-related multi-organ lymphoproliferative syndrome (IgG 4-MOLPS). Research Committee to establish diagnostic criteria and development of treatment for systemic IgG4-related sclerosing disease, et al. Nihon Naika Gakkai Zasshi. 2012 Mar 10;101(3):795-804. doi: 10.2169/naika.101.795. Nihon Naika Gakkai Zasshi. 2012. PMID: 22620057 Japanese. No abstract available.
The 2023 revised diagnostic criteria for IgG4-related dacryoadenitis and sialadenitis.
Kanda M, Nagahata K, Moriyama M, Takano KI, Kamekura R, Yoshifuji H, Tsuboi H, Yamamoto M, Umehara H, Umeda M, Sakamoto M, Maehara T, Inoue Y, Kubo S, Himi T, Origuchi T, Masaki Y, Mimori T, Dobashi H, Tanaka Y, Nakamura S, Takahashi H. Kanda M, et al. Among authors: umehara h. Mod Rheumatol. 2024 Oct 23:roae096. doi: 10.1093/mr/roae096. Online ahead of print. Mod Rheumatol. 2024. PMID: 39441008
Inebilizumab for Treatment of IgG4-Related Disease.
Stone JH, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, Löhr JM, Schleinitz N, Dong L, Umehara H, Lanzillotta M, Wallace ZS, Ebbo M, Webster GJ, Martinez Valle F, Nayar MK, Perugino CA, Rebours V, Dong X, Wu Y, Li Q, Rampal N, Cimbora D, Culver EL; MITIGATE Trial Investigators. Stone JH, et al. Among authors: umehara h. N Engl J Med. 2024 Nov 14. doi: 10.1056/NEJMoa2409712. Online ahead of print. N Engl J Med. 2024. PMID: 39541094
Clinical profile of IgG4-related disease in Japan based on the rare disease data registry.
Yamamoto M, Kanda M, Mizushima I, Kanno A, Umemura T, Ikeura T, Kodama Y, Dobashi H, Tanaka Y, Masamune A, Moriyama M, Saeki T, Matsui S, Origuchi T, Masaki Y, Asada M, Umehara H, Seno H, Naitoh I, Yamamoto S, Iwasaki E, Kubota K, Tanoue S, Nishino T, Tsuboi H, Matsumoto Y, Isayama H, Goto H, Notohara K, Uchida K, Kawabe K, Yamada K, Kasashima S, Takahira M, Sato Y, Kawachi I, Yamaguchi I, Okazaki K, Nakamura S, Matsuda F, Ishikawa H, Kawano M; Patient Registry Committee, Research Program for Intractable Disease by the Ministry of Health, Labour and Welfare (MHLW), Japan; *Other than the co-authors, the members of Patient Registry Committee, Research Program for Intractable Disease by the Ministry of Health, Labour and Welfare (MHLW), Japan are as follows: Kensuke Yokoyama (Jichi Medical University);. Yamamoto M, et al. Among authors: umehara h. Immunol Med. 2024 Nov 28:1-11. doi: 10.1080/25785826.2024.2430812. Online ahead of print. Immunol Med. 2024. PMID: 39607031 Free article.
Association Between Dynapenia/Sarcopenia, Extrapyramidal Symptoms, Negative Symptoms, Body Composition, and Nutritional Status in Patients with Chronic Schizophrenia.
Kamoi R, Mifune Y, Soriano K, Tanioka R, Yamanaka R, Ito H, Osaka K, Umehara H, Shimomoto R, Bollos LA, Kwan RYC, Endo I, Palijo SS, Noguchi K, Mifune K, Tanioka T. Kamoi R, et al. Among authors: umehara h. Healthcare (Basel). 2024 Dec 30;13(1):48. doi: 10.3390/healthcare13010048. Healthcare (Basel). 2024. PMID: 39791654 Free PMC article.
Schizophrenia and cognitive dysfunction.
Takeda T, Umehara H, Matsumoto Y, Yoshida T, Nakataki M, Numata S. Takeda T, et al. Among authors: umehara h. J Med Invest. 2024;71(3.4):205-209. doi: 10.2152/jmi.71.205. J Med Invest. 2024. PMID: 39462553 Free article. Review.
293 results